Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

7792 ARTÍCULOS , VIENDO DEL 2491 AL 2505

Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data

Mu L, Xu J, Ye X, Jiang Y, Yi Z.

BMC Pharmacol Toxicol. 2025 Mar 10;26(1):54. doi: 10.1186/s40360-025-00886-3.

Psychometric properties of outcome measures for freezing of gait in Parkinson's disease: a systematic review and meta-analysis

Proietti P, Ruotolo I, Carlizza A, Ugolini A, Galeoto G, Fabbrini G, Sellitto G.

Expert Rev Pharmacoecon Outcomes Res. 2025 Jun;25(5):647-659. doi: 10.1080/14737167.2025.2477473. Epub 2025 Mar 13.

COVID-19 Presenting With Intractable Hiccups: A Literature Review and a New Case

Aloqaily M, Tarazi A, Ammar A, Alfarrajin I, Ababneh R, Aloqaily WA, Alasaad Y.

Cureus. 2025 Feb 7;17(2):e78701. doi: 10.7759/cureus.78701. eCollection 2025 Feb.

Comparing manual and automated methods for calculating speaking rate in Parkinson's disease

Arzbecker LJ, Stipancic KL, Greenlee JDW, Tjaden K.

JASA Express Lett. 2025 Mar 1;5(3):035203. doi: 10.1121/10.0036021.

Rhythmic Eyelid Closure Responsive to STN-DBS: Blepharoclonus, Blepharospasm, Eyelid Opening Apraxia, or Eyelid Tremor?

Gaudiano G, Boogers A, Grippe T, Cilia R, Eleopra R, Chen R, Fasano A.

Mov Disord Clin Pract. 2025 Jul;12(7):1020-1023. doi: 10.1002/mdc3.70030. Epub 2025 Mar 11.

Efficacy and safety of GLP-1 agonists in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials

Messak M, Abdelmageed A, Senbel AA, Khattab YA, Mandour Y, Shaker O, Rehan AH, Oransa S, Nasr M, Shabeeb AE, Rezq Z, Hossam F, Abouelmagd ME.

Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug;398(8):9721-9736. doi: 10.1007/s00210-025-03932-3. Epub 2025 Mar 11.

Nanomedicine: a cost-effective and powerful platform for managing neurodegenerative diseases

Hassanzadeh-Khanmiri M, Moshari A, Kheradmand R, Haghgouei T, Homaei M, Charsouei S, Mobed A.

Metab Brain Dis. 2025 Mar 11;40(3):142. doi: 10.1007/s11011-025-01564-3.

Correction: Spatiotemporal patterns of brain iron-oxygen metabolism in patients with Parkinson's disease

Yan S, Lu J, Li Y, Cho J, Zhang S, Zhu W, Wang Y.

Eur Radiol. 2025 Sep;35(9):5872-5874. doi: 10.1007/s00330-025-11435-1.

Advances in the study of depression and anxiety in Parkinson's disease: A review

Wang Z, Wei H, Xin Y, Qin W.

Medicine (Baltimore). 2025 Mar 7;104(10):e41674. doi: 10.1097/MD.0000000000041674.

Parkinson's disease: News on the action of melatonin

Scorza FA, Wuo-Silva R, Finsterer J, Chaddad-Neto F.

Sleep Med. 2025 Jun;130:1-2. doi: 10.1016/j.sleep.2025.02.038. Epub 2025 Feb 28.

Unraveling the role of the IL-20 cytokine family in neurodegenerative diseases: Mechanisms and therapeutic insights

Goleij P, Amini A, Tabari MAK, Hadipour M, Rezaee A, Daglia M, Aschner M, Sanaye PM, Kumar AP, Khan H.

Int Immunopharmacol. 2025 Apr 16;152:114399. doi: 10.1016/j.intimp.2025.114399. Epub 2025 Mar 10.

Diagnostics and Ecological Validity of the Italian Version of the Parkinson's Disease Cognitive Rating Scale

D'Iorio A, Aiello EN, Vitale C, Amboni M, Verde F, Silani V, Ticozzi N, Ciammola A, Poletti B, Santangelo G.

Dement Geriatr Cogn Disord. 2025;54(5):347-351. doi: 10.1159/000545090. Epub 2025 Mar 11.

Epigenetic regulation of iron metabolism and ferroptosis in Parkinson's disease: Identifying novel epigenetic targets

Gao XD, Ding JE, Xie JX, Xu HM.

Acta Pharmacol Sin. 2025 Aug;46(8):2075-2092. doi: 10.1038/s41401-025-01499-6. Epub 2025 Mar 11.

Investigation of the Impact of Motor, Nonmotor, Cognitive, and Psychometric Features on Freezing of Gait in Parkinson's Disease

Onder H, Aydogan A, Ulker AC, Comoglu S.

Eur J Neurosci. 2025 Mar;61(5):e70044. doi: 10.1111/ejn.70044.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias